ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Su Huang, Khadijeh Bijangi-Vishehsaraei, Mohammad Reza Saadatzadeh, Ahmad R. Safa
Background: Taxol (paclitaxel) inhibits proliferation and induces apoptosis in a variety of cancer cells, but it also upregulates cytoprotective proteins and/or pathways that compromise its therapeutic efficacy. Materials and Method: The roles of GM3 synthase…
Han Shen, Kerrie L. McDonald
Glioblastoma is a highly malignant primary tumor of the central nervous system tumor with a poor survival rate. The treatment of glioblastoma is shifting from a purely cytotoxic approach to one that incorporates anti-angiogenic agents. Bevacizumab (Avastin ;…
Robert Eil, Kim C. Lu, George R. Wettach, Vassiliki L. Tsikitis
A 42-year-old male with a history of recurrent intracranial hemangiopericytoma presented to the Emergency Department with urinary retention. Ensuing work-up revealed a 10-centimeter circumscribed pelvic mass that appeared anatomically distinct from the sacrum…
Josep M. Gaya, Juan Palou, Oscar Rodríguez, Humberto Villavicencio
Bladder cancer is a common disease that is often detected late and has a high rate of recurrence and progression. The current standard of care for the primary detection and follow-up of NMIBC consists of urethro-cystoscopy associated with cytology. However, s…
Nazem Shams, Mahmoud Mosbah, Mohammad Hegazy, Osama Hussein, Omar Farouk, Sameh Roshdy, Mohamed Tarek Hafez, Ashraf Khater, Khaled Abdel Wahab
Background: Pancreatic cancer is the fourth most common cause of cancer related deaths in the world. Surgical resection remains the only potentially curative treatment for adenocarcinoma of the pancreas; only 10% - 20% of patients are candidate for standard p…
Enoch Chan, Thevaki Sivagnanam, Qi Zhang, Craig R. Lewis, Paul S. Thomas
Background and Aims: Lung cancer is a leading cause of cancer mortality worldwide and is associated with the release of tumour necrosis factor-α (TNF-α), subsequent cellular apoptosis and the generation of oxidative stress. Exhaled breath condensate (EBC) ana…
Yinan Liu, Andrew J. Sanders, Lijian Zhang, Wen G. Jiang
Epithelial Protein Lost in Neoplasm (EPLIN) is a cytoskeletal associated protein implicated in regulating actin dynamoics and cellular motility and whose expression is frequently downregulated in a number of human cancers. The current study examined the expre…
Gerhard Hamilton, Ernst Ulsperger, Klaus Geissler, Ulrike Olszewski
Extended stage small cell lung cancer (SCLC) responds to platinum/vepeside-based first-line chemotherapy but relapses early as drug-resistant tumor associated with a dismal prognosis. A pair of SCLC cell lines obtained from a single patient at different time…
Ning Li, Bin Qu, Kang Shao, Zhaoli Chen, Fengwei Tan, Xiaogang Tan, Baozhong Li, Jiwen Wang, Jie He
Introduction: Smoking and non-smoking lung cancer have many differences in clinical feature. But those may be the result of interference due to differences in pathological type, as most smoking patients suffer squmous cell lung cancer and non-smokings tend to…
Kenji Takeuchi, Anh Ho Viet, Katsumi Kawasaki, Kazuto Nishio, Fumiaki Ito
BIM, a key proapoptotic member of the BCL-2 family of proteins, is essential for apoptosis triggered by tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR). However, the precise molecular mechanism by which EGFR-TKIs induce BIM ex…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).